Eloise Williams MBBS , Soo Jen Low PhD , Georgina L Pollock PhD , Mona L Taouk BSc , Jacqueline Prestedge BSc , Benjamin P Howden PhD , Eric P F Chow PhD , Christopher K Fairley PhD , Kate L Seib PhD , James S McCarthy MD , Shivani Pasricha PhD , Deborah A Williamson PhD
{"title":"选择候选淋病奈瑟菌用于口咽淋病人类挑战:基于基因组学的临床分离株分析。","authors":"Eloise Williams MBBS , Soo Jen Low PhD , Georgina L Pollock PhD , Mona L Taouk BSc , Jacqueline Prestedge BSc , Benjamin P Howden PhD , Eric P F Chow PhD , Christopher K Fairley PhD , Kate L Seib PhD , James S McCarthy MD , Shivani Pasricha PhD , Deborah A Williamson PhD","doi":"10.1016/j.lanmic.2025.101105","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><em>Neisseria gonorrhoeae</em> is a human pathogen of major public health importance due to its increasing global prevalence and antimicrobial resistance (AMR). Evidence suggests that oropharyngeal infection plays a key role in <em>N gonorrhoeae</em> transmission and AMR; however, our understanding of oropharyngeal gonorrhoea pathogenesis is poor. A controlled human infection model (CHIM) for oropharyngeal gonorrhoea will improve understanding of infection and accelerate urgently needed novel gonorrhoea prevention and therapeutic strategies. As the first step in the development of this CHIM, we describe a systematic approach to CHIM strain selection that leverages genomics and clinical data.</div></div><div><h3>Methods</h3><div>In this genomics-based analysis, we applied a systematic <em>N gonorrhoeae</em> challenge strain selection strategy incorporating genomic and clinical data to a primary dataset of clinical isolates of <em>N gonorrhoeae</em> collected from adult patients in Victoria, Australia, between Jan 1 and Dec 31, 2017, and July 1, 2019, and June 30, 2021. This selection strategy used clinical, phenotypic, and genomic characteristics to define a set of eight criteria that aimed to ensure the contemporary global clinical relevance of the candidate strains; select strains that would be applicable for the assessment of current and future gonorrhoea vaccines; and maximise participant safety by reducing the risk of disseminated gonococcal infection and clinically significant AMR. We applied these criteria to our primary dataset to generate a panel of potential challenge strains. From this final dataset of potential challenge strains, we predetermined that we would select up to ten isolates to proceed to the next stage of detailed phenotypic characterisation for final <em>N gonorrhoeae</em> CHIM strain selection.</div></div><div><h3>Findings</h3><div>5881 isolates comprised the primary dataset. After application of the selection criteria, most of the isolates (5795 [98·6%] of 5881) were excluded, mostly due to having clinically significant AMR and poor contemporary global clinical relevance. The remaining 86 <em>N gonorrhoeae</em> challenge strain candidates comprised five multilocus sequence types and six <em>N gonorrhoeae</em> multiantigen sequence types, many of which were represented by a single isolate. Of these 86 strains, five isolates were selected to maximise coverage of the phylogenetically distinct groups within the 86 candidate challenge strains and ensure representation of strains collected from various anatomical sites.</div></div><div><h3>Interpretation</h3><div>We transparently describe a novel, systematic, and rational genomics-based strategy for oropharyngeal gonorrhoea CHIM strain selection that improves the efficiency and transparency of CHIM strain selection and enables identification of contemporary and clinically relevant potential challenge strains. A final <em>N gonorrhoeae</em> challenge strain will be selected from the subset of five shortlisted candidates after detailed phenotypic assessment.</div></div><div><h3>Funding</h3><div>Medical Research Future Fund, Australian National Health and Medical Research Council and Australian Government Research Training Program.</div></div>","PeriodicalId":46633,"journal":{"name":"Lancet Microbe","volume":"6 9","pages":"Article 101105"},"PeriodicalIF":20.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Selecting candidate Neisseria gonorrhoeae strains for oropharyngeal gonorrhoea human challenge: a genomics-based analysis of clinical isolates\",\"authors\":\"Eloise Williams MBBS , Soo Jen Low PhD , Georgina L Pollock PhD , Mona L Taouk BSc , Jacqueline Prestedge BSc , Benjamin P Howden PhD , Eric P F Chow PhD , Christopher K Fairley PhD , Kate L Seib PhD , James S McCarthy MD , Shivani Pasricha PhD , Deborah A Williamson PhD\",\"doi\":\"10.1016/j.lanmic.2025.101105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div><em>Neisseria gonorrhoeae</em> is a human pathogen of major public health importance due to its increasing global prevalence and antimicrobial resistance (AMR). Evidence suggests that oropharyngeal infection plays a key role in <em>N gonorrhoeae</em> transmission and AMR; however, our understanding of oropharyngeal gonorrhoea pathogenesis is poor. A controlled human infection model (CHIM) for oropharyngeal gonorrhoea will improve understanding of infection and accelerate urgently needed novel gonorrhoea prevention and therapeutic strategies. As the first step in the development of this CHIM, we describe a systematic approach to CHIM strain selection that leverages genomics and clinical data.</div></div><div><h3>Methods</h3><div>In this genomics-based analysis, we applied a systematic <em>N gonorrhoeae</em> challenge strain selection strategy incorporating genomic and clinical data to a primary dataset of clinical isolates of <em>N gonorrhoeae</em> collected from adult patients in Victoria, Australia, between Jan 1 and Dec 31, 2017, and July 1, 2019, and June 30, 2021. This selection strategy used clinical, phenotypic, and genomic characteristics to define a set of eight criteria that aimed to ensure the contemporary global clinical relevance of the candidate strains; select strains that would be applicable for the assessment of current and future gonorrhoea vaccines; and maximise participant safety by reducing the risk of disseminated gonococcal infection and clinically significant AMR. We applied these criteria to our primary dataset to generate a panel of potential challenge strains. From this final dataset of potential challenge strains, we predetermined that we would select up to ten isolates to proceed to the next stage of detailed phenotypic characterisation for final <em>N gonorrhoeae</em> CHIM strain selection.</div></div><div><h3>Findings</h3><div>5881 isolates comprised the primary dataset. After application of the selection criteria, most of the isolates (5795 [98·6%] of 5881) were excluded, mostly due to having clinically significant AMR and poor contemporary global clinical relevance. The remaining 86 <em>N gonorrhoeae</em> challenge strain candidates comprised five multilocus sequence types and six <em>N gonorrhoeae</em> multiantigen sequence types, many of which were represented by a single isolate. Of these 86 strains, five isolates were selected to maximise coverage of the phylogenetically distinct groups within the 86 candidate challenge strains and ensure representation of strains collected from various anatomical sites.</div></div><div><h3>Interpretation</h3><div>We transparently describe a novel, systematic, and rational genomics-based strategy for oropharyngeal gonorrhoea CHIM strain selection that improves the efficiency and transparency of CHIM strain selection and enables identification of contemporary and clinically relevant potential challenge strains. A final <em>N gonorrhoeae</em> challenge strain will be selected from the subset of five shortlisted candidates after detailed phenotypic assessment.</div></div><div><h3>Funding</h3><div>Medical Research Future Fund, Australian National Health and Medical Research Council and Australian Government Research Training Program.</div></div>\",\"PeriodicalId\":46633,\"journal\":{\"name\":\"Lancet Microbe\",\"volume\":\"6 9\",\"pages\":\"Article 101105\"},\"PeriodicalIF\":20.4000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Microbe\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666524725000333\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Microbe","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666524725000333","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Selecting candidate Neisseria gonorrhoeae strains for oropharyngeal gonorrhoea human challenge: a genomics-based analysis of clinical isolates
Background
Neisseria gonorrhoeae is a human pathogen of major public health importance due to its increasing global prevalence and antimicrobial resistance (AMR). Evidence suggests that oropharyngeal infection plays a key role in N gonorrhoeae transmission and AMR; however, our understanding of oropharyngeal gonorrhoea pathogenesis is poor. A controlled human infection model (CHIM) for oropharyngeal gonorrhoea will improve understanding of infection and accelerate urgently needed novel gonorrhoea prevention and therapeutic strategies. As the first step in the development of this CHIM, we describe a systematic approach to CHIM strain selection that leverages genomics and clinical data.
Methods
In this genomics-based analysis, we applied a systematic N gonorrhoeae challenge strain selection strategy incorporating genomic and clinical data to a primary dataset of clinical isolates of N gonorrhoeae collected from adult patients in Victoria, Australia, between Jan 1 and Dec 31, 2017, and July 1, 2019, and June 30, 2021. This selection strategy used clinical, phenotypic, and genomic characteristics to define a set of eight criteria that aimed to ensure the contemporary global clinical relevance of the candidate strains; select strains that would be applicable for the assessment of current and future gonorrhoea vaccines; and maximise participant safety by reducing the risk of disseminated gonococcal infection and clinically significant AMR. We applied these criteria to our primary dataset to generate a panel of potential challenge strains. From this final dataset of potential challenge strains, we predetermined that we would select up to ten isolates to proceed to the next stage of detailed phenotypic characterisation for final N gonorrhoeae CHIM strain selection.
Findings
5881 isolates comprised the primary dataset. After application of the selection criteria, most of the isolates (5795 [98·6%] of 5881) were excluded, mostly due to having clinically significant AMR and poor contemporary global clinical relevance. The remaining 86 N gonorrhoeae challenge strain candidates comprised five multilocus sequence types and six N gonorrhoeae multiantigen sequence types, many of which were represented by a single isolate. Of these 86 strains, five isolates were selected to maximise coverage of the phylogenetically distinct groups within the 86 candidate challenge strains and ensure representation of strains collected from various anatomical sites.
Interpretation
We transparently describe a novel, systematic, and rational genomics-based strategy for oropharyngeal gonorrhoea CHIM strain selection that improves the efficiency and transparency of CHIM strain selection and enables identification of contemporary and clinically relevant potential challenge strains. A final N gonorrhoeae challenge strain will be selected from the subset of five shortlisted candidates after detailed phenotypic assessment.
Funding
Medical Research Future Fund, Australian National Health and Medical Research Council and Australian Government Research Training Program.
期刊介绍:
The Lancet Microbe is a gold open access journal committed to publishing content relevant to clinical microbiologists worldwide, with a focus on studies that advance clinical understanding, challenge the status quo, and advocate change in health policy.